MedMira receives European order for 400,000 MiraCare HIV tests

By Lisa Kerner

Erie, Pa., Jan. 11 - MedMira Inc., said it has received an order for 400,000 MiraCare Rapid HIV Antibody Tests from its distributor in Spain. MedMira will fulfill this order over a preset timeframe, upon receipt of a CE Mark.

The distributor will target pharmacies and hospitals, as well as laboratories for initial sales of the MiraCare test.

This is the first significant order of the MiraCare tests destined for the European market, according to a company news release.

"This order is a significant milestone for MedMira in Europe. It is just the beginning of our strategic market push throughout the region," Stephen Sham, MedMira chairman and chief executive officer said in the release. "We have put a great deal of time and effort into establishing a solid network of qualified distributors and obtaining regulatory approval necessary to bring MiraCare to the EU market."

MiraCare will be the fastest rapid HIV test available in Europe, taking less than three minutes to perform and providing test results instantly, said the release. It will also be the only North American-made rapid HIV test to be approved and sold in Europe.

More than 2 million people in Europe are living with HIV, according to EuroHIV, the European HIV/AIDS surveillance network.

MiraCare was launched in 2005 in Hong Kong and Macau.

MedMira, based in Halifax, Nova Scotia, manufactures and markets in vitro flow-through rapid diagnostic tests to detect human antibodies in human serum, plasma or whole blood for diseases such as HIV and hepatitis C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.